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Background: Surgery is still the standard treatment for aggressive fibromatosis (AF); however, local control
remains a significant problem and the impact of R0 surgery on cumulative recurrence (CR) is objective of
contradictory reports.
Methods: This is a single-institution study of 62 consecutive patients affected by extra-abdominal and
intra-abdominal AF who received macroscopically radical surgery within a time period of 15 years.
Results: Definitive pathology examination confirmed an R0 situation in 49 patients and an R1 in 13 patients.
Five-year CR for patients who underwent R0 vs R1 surgery was 7.1% vs 46.4% (P= 0.04) and for limbs vs other
localizations 33.3% vs 9.9% (P= 0.02) respectively. In 17 patients who had intraoperative frozen section (IFS)
margin evaluation R0 surgery was more common (17 of 17 vs 32 of 45, P= 0.01) and CR lower (five-year CR 0% vs
19.1%, respectively, P= 0.04). However, in multivariate analysis only limb localization showed a negative impact
on CR (HR: 1.708, 95% CI 1.03 to 2.84, P= 0.04).
Conclusions: IFS evaluation could help the surgeon to achieve R0 surgery in AF. Non-surgical treatment, including
watchful follow-up, could be indicated for patients with limb AF localization, because of their high risk of
recurrence even after R0 surgery.
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Among soft tissue neoplasms, desmoids tumors, also
called aggressive fibromatosis, account for less than 3%
(0.03 of all tumors). These neoplasms do not have meta-
static potential but tend to locally infiltrate the musculo-
aponeurotic structures [1]. Local control of aggressive
fibromatosis (AF) remains a significant problem, with
an average recurrence rate of 24 to 77% no matter
what therapeutic modality is used [2]. Surgery is the pri-
mary therapy for extra-abdominal and abdominal wall
desmoid tumors; however, the identification of inform-
ative prognostic factors, such as margins (R0 surgery),* Correspondence: emilio.bertani@ieo.it
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reproduction in any medium, provided the orlocalization, diameter and so on is still controversial. Of
particular importance for the surgeon is the prognostic
significance of R0 surgery in planning the width of resec-
tion, especially when the surgical site is challenging and
surgery has the risk of short- and long-term postopera-
tive complications. In addition, alternative approaches,
such as radiotherapy [3,4], COX-2 inhibitors [5], anti-
estrogens, interferon alpha, vitamin C [6], cytotoxic
chemotherapy [7,8] and imatinib [9], have shown various
degrees of efficacy. Observation alone is increasingly
recommended for static lesions, given the morbidity
associated with surgical resection and frequent disease
recurrence [10,11]. Therefore, a consensus over the
standard of care is limited and weakened by heteroge-
neous treatments and lack of large studies. In this con-
text, the aim of the present study was to analyze the roleLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the other risk factors for AF recurrence in a consecutive
surgical series of patients homogeneously treated at a
single institute.
Methods
From 1994 to 2010, 73 patients affected by AF were
observed at the European Institute of Oncology and
their records were extracted from the institute’s tumor
registry, a prospective desmoid tumor database contain-
ing 65 data fields. Eleven patients had a histologically
confirmed diagnosis of AF in the resected specimen or
pathology review in our institute. One patient was
affected by familial adenomatous polyposis coli (FAP).
Sixty-three patients underwent surgery (86.3%), while
the remaining 10 patients were judged unresectable.
Among this latter group, two cases underwent low-dose
chemotherapy, three were given COX-2 inhibitors with
or without tamoxifen, while four patients were put
under observation. Of the 63 surgically treated patients,
62 (98%) received macroscopically radical surgery (R0 or
R1 according to AJCC) [12] and form the body of the
analysis in the present study. Written informed consent
was obtained from the patients for publication of this
report and any accompanying images.
Pre-treatment work-up
Twenty-eight patients were studied by magnetic reson-
ance imaging (MRI), and 34 by computed tomography
(CT) scan. Ultrasound (US) examination was the only
diagnostic tool employed before treatment for 10 patients.
US-guided core biopsy (Gallini- Mantova, Italy ) was per-
formed in 44 cases (71%), which was diagnostic for AF in
37 patients and nondiagnostic in the remaining 7.
Surgical technique
Surgical principles that aided resection comprised a wide
excision of the mass, which involved the removal of all
gross disease together with a normal tissue rim of at
least 1 cm whenever possible [13]. For this purpose,
intraoperative frozen section (IFS) margin evaluation
was employed in those cases that the operating surgeon
deemed at risk of margin involvement. All operations
were performed under antibiotic cover with third gener-
ation cephalosporin, which was continued until the suc-
tion drains were removed. Low molecular weight
heparins were administered starting from the first pre-
operative day and were continued for one month follow-
ing surgery to prevent thromboembolic disease.
Pathology examination
Both the surgical specimen and margin biopsy where ne-
cessary were oriented by the surgeon and inked by the
pathologist. In cases of IFS diagnosis, the pathologistexamined all the margins if the neoplasm was ill-defined
or the closest margin to neoplasia in the case of a clearly
recognizable mass. Biopsy specimens were analyzed in
their entirety. If neoplastic cells were detected on the
inked margin examined, further surgery was performed
until negative microscopic margins were achieved [14].
A histological diagnosis of aggressive fibromatosis was
obtained in all operated cases. Whenever deemed neces-
sary, appropriate immunohistology was performed as an
adjunct to the morphological evaluation of the neoplasia.
Tumor characteristics studied included site and size: the
size was obtained by measuring the largest dimension of
the tumor in the surgical specimen and by MRI or CT
scan for non-operated patients.
Follow-up and recurrence
Follow-up was by outpatient clinical appointments, with
clinical and radiological assessment as indicated. Recur-
rence was diagnosed radiologically and confirmed by
percutaneous biopsy when appropriate. No patient was
lost to follow-up.
Statistical analysis
The Chi-square test and the Fisher exact test were used,
as appropriate, to compare distributions of categorical
variables. The crude cumulative incidence of tumor
recurrences was computed in a competing risk frame-
work, with deaths without recurrence treated as com-
peting events. Cumulative incidences were compared
across subgroups by means of the Gray test. A multi-
variable Cox regression model was used to test the
independent prognostic value of the variables which
showed significant results in the univariate analysis.
Adjusted hazard ratios (HR) with 95% confidence inter-
vals (CIs) were reported. All analyses were carried out
with the SAS software (SAS Institute, Cary, NC, USA)
and the R (http://cran.r-project.org/) software. All the
reported P-values were two-sided.
Results
There were 43 females and 19 males (median age
36 years, range 16 to 76 years) affected by primary (52)
or recurrent (10) disease. In order to optimize surgical
outcome (at least 1 cm of free margin whenever pos-
sible) intraoperative frozen section (IFS) evaluation was
employed in 17 cases. In six of these cases it was per-
formed twice because the first IFS examination reported
a microscopically involved margin. Definitive pathology
examination confirmed an R0 situation in 49 patients
and R1 in 13 patients. No cases of discordance between
the last intraoperative and the final margin evaluation
(R0 vs R1) were registered among the 17 patients who
had IFS evaluation (Table 1). The probability of receiving
IFS evaluation was not correlated to the tumor size (3 of
Table 1 Factors associated with the achievement of R0 surgery for the 62 radically resected patients
Variable Classification R0
N=49
R1
N=13
P-value
Age ≤36 24 (77.4) 7 (22.6) 0.76
>36 25 (80.7) 6 (19.4)
Gender M 15 (78.9) 4 (21.1) 1.00
F 34 (79.1) 9 (20.9)
Recurrence at presentation Yes 8 (80.0) 2 (20.0) 1.00
No 41 (78.8) 11 (21.2)
Site of tumor Trunk 33 (78.6) 9 (21.4) 0.35
Head and neck 4 (57.1) 3 (42.9)
Limbs 6 (85.7) 1 (14.3)
Mesentery 6 (100) 0 (0.0)
Limb localization Yes 6 (85.7) 1 (14.3) 1.00
No 43 (78.2) 12 (21.8)
Tumor maximum diameter <10 cm 40 (80.0) 10 (20.0) 0.70
≥10 cm 9 (75.0) 3 (25.0)
IFS* No 32 (71.1) 13 (28.9) 0.01
Yes 17 (100.0) 0 (0.0)
Postoperative RT} No 46 (83.6) 9 (16.4) 0.03
Yes 3 (42.9) 4 (57.1)
*IFS, intraoperative frozen sections; }RT, radiotherapy.
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P= 0.83). R1 patients were more likely to receive post-
operative radiotherapy (Table 1).
Follow-up and survival
After a median follow-up time of 66 months (range 2 to
175) two deaths related to the disease were registered.
These deaths were not caused by recurrence of the dis-
ease, but by long-term complications of treatment. In
one case, a 30 year-old male patient affected by a huge
intra-abdominal recurrent desmoid, who underwent
radical surgery at our institute, died after 14 months
becaus of rejection after small bowel transplantation.
The other case was a 54 year-old male affected by a
cervico-thoracic desmoid, who underwent a huge demo-
lition of the thoracic wall and pulmonary resection, fol-
lowed by radiotherapy as a result of the pathology
findings of R1 surgery, and developed a pulmonary my-
cetoma that was resected 32 months after the primary
surgery. He died from subsequent complications four
months thereafter. Three other patients died during
follow-up due to causes other than fibromatosis (one for
cardiovascular event, the other two for advanced colo-
rectal cancer). For these reasons, actuarial five-year over-
all survival was 95% in our series.
Risk factors affecting cumulative recurrence (CR)
Seven patients developed recurrence during follow-up
that arose within the surgical field in four cases, andwithin the same anatomical region, but distant from the
surgical field, in the remaining three patients. Of these
seven patients, three underwent repeated surgery that
was demonstrated to be R0 in all three cases. At this
time all three patients are alive and disease-free. None of
the patients who had IFS examination developed recur-
rence during follow-up.
Actuarial CR was 8%, 13%, 16% at three to five and
eight years respectively. Univariate analysis of possible
factors affecting CR is reported in Table 2. R1 surgery,
(Figure 1), tumor maximum diameter ≥10 cm and limb
localization (vs any other) (Figure 2) were associated
with significantly higher CR rates. Patients who had IFS
margin evaluation showed a significantly lower CR (no
recurrences in that group) in comparison with patients
who did not have such an assessment (Figure 3). In
multivariate analysis only limb localization was signifi-
cantly associated with higher CR (Table 3).
Discussion
Despite the rarity of this disease, several reports exist on
prognostic factors for recurrence after resection of AF
[15-24]. However, to minimize recurrence, clear indica-
tions on how to perform surgery and analyze AF speci-
mens are lacking. In the current single-center study, R1
surgery, tumor diameter (≥10 cm) and limb localization
were the most significant prognostic factors associated
with higher CR in a consecutive series of desmoid
tumors. The achievement of a microscopically negative
Table 2 Factors affecting CR rate for the 62 patients who underwent macroscopically radical tumor resection
Variable Classification At risk Recurrences (% 5-year cumulative incidence) P-value
All patients 62 7 (12.8)
Age ≤36 31 5 (19.2) 0.30
>36 31 2 (5.0)
Gender M 19 2 (13.1) 0.74
F 43 5 (12.2)
Recurrence at
presentation Yes 10 3 (10.6) 0.17
No 52 4 (20.0)
Site of tumor Trunk 42 1 (7.8) 0.09
Head and neck 7 1 (16.7)
Limbs 7 3 (33.3)
Mesentery 6 2 (16.7)
Limb localization Yes 7 3 (33.3) 0.02
No 55 4 (9.9)
Residual tumor R0 49 4 (7.1) 0.04
R1 13 3 (46.4)
Tumor maximum diameter <10 cm 50 4 (8.1) 0.05
≥10 cm 12 3 (31.8)
IFS* No 45 7 (19.1) 0.04
Yes 17 0 (0.0)
*IFS, intraoperative frozen sections.
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dictor of R0 resection and lower CR, where none of the
17 negative IFS specimens was demonstrated to have
microscopic infiltration of the margin at definitive path-
ology stain and none of the patients receiving IFS devel-
oped recurrence. This finding is limited by the lack of
randomization and by the fact that IFS was employed in
only 27% of patients from our series, so that we do not
have sufficient data supporting a further reduction of R1
cases with increased use of IFS. Strict cooperation be-
tween the team of doctors involved in the management
of this disease is of particular importance in achieving
successful R0 surgery. The anatomical surgery should be
accurately evaluated for a more complete radicality, and
the margin at risk of involvement clearly indicated by
the surgeon to the pathologist. In addition, pathologists
should be fully aware of the characteristics of the disease
that they are dealing with, which is often infiltrating, and
of any previous treatment, such as radiotherapy or sur-
gery, in order to better interpret any findings of fibrosis,
inflammatory cells or cellular atypia in particular at the
time when a correct margin definition is needed.
The impact of a negative surgical margin after surgery
for desmoid tumors has been widely debated in the lit-
erature. In a recently published French study [15], the
largest series of sporadic desmoids, progression-free sur-
vival curves were not significantly different in terms ofmicroscopic assessment of surgical resection quality (R0
vs R1), although R2 resections showed a significantly
poorer prognosis. This French study, which retrospect-
ively entered into a database the data of 426 patients
from 24 participating centers starting from 1965, showed
a five-year progression-free survival rate of 62.5% for R0
resections, which compares unfavorably with our figure
of 92.9%. This difference is difficult to explain, but if we
consider that RFS rates for R1 cases are quite similar
(60.5% vs 53.6%), it is arguable that in a large multi-
centric study enrolling very early cases, a problem may
be the lack of standardization mainly for pathological as-
sessment of margins (for example, definition of “R0” and
“R1” resections). In the study conducted by the Italian
National Tumour Institute (INT) [16], the presence of
microscopic disease in one surgical margin assumed
prognostic relevance in patients with an already recur-
rent disease but not in patients with primary lesions. In-
deed, data from Memorial Sloan-Kettering Cancer
Centre (MSKCC) [17] , Mirabell et al. [18], Reitamo
et al. [19] made the same observations. Conversely, and
in line with our data, other authors [20-22] identified a
positive resection margin as the most important inde-
pendent predictive factor of local recurrence.
We identify the subgroup of patients affected by AF
limb localizations to be at risk for recurrence even after
radical surgery. This finding is similar to that of several
Figure 1 Impact of R0 vs R1 surgery on CR for the 62 patients.
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the University of Texas [23] (UTMDACC) authors com-
pared two consecutive series of desmoids tumors investi-
gating differences of approach and outcome between an
earlier group of patients treated from 1965 to 1994 andFigure 2 Impact of tumor localization (limbs vs no limbs).a recent group treated from 1995 to 2005. Interestingly,
in the most recent series only extremity site and age ≤30
were prognostic factors for recurrence. Although in that
group patients with positive margins were generally
more likely to undergo adjuvant therapy (53% vs 23%),
Figure 3 Impact of performing IFS on CR.
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provement in disease-free survival in the recent series,
even in the presence of a higher rate of positive margins.
Objective evaluation of efficacy is affected by the lack
of prospective studies comparing local recurrence in
comparison to, or in combination with, surgery. For
radiotherapy, in the presence of microscopically positive
margins, improved recurrence-free survival reported by
UTMDACC [23] and Massachusetts General Hospital
(MGH) [24] is counterbalanced by negative findings of
MSKCC [17] and INT [16] studies. The indication for
adjuvant radiotherapy for each patient of our series was
evaluated within a framework of a multidisciplinary team
comprising surgeons and radiotherapists. This resulted
in a significantly higher probability for patients who
underwent R1 surgery to receive postoperative radiother-
apy (3 of 49 after R0 vs 4 of 13 after R1 surgery, Table 1).
The good results after R0 surgery in this series are to
be considered in the light of the relatively high all-
causes mortality that occurred during follow-up, despite
the median age of the whole group of patients beingTable 3 Multivariate analysis of factors affecting CR
HR 95 % CI P-value
Limb localization* 1.71 1.03 to 2.84 0.04
R1 surgery} 2.94 0.47 to 18.20 0.25
Tumor size (≥10 cm) 2.68 0.43 to 16.67 0.29
Abbreviation: HR, hazard ratio.
*Limbs vs all other localizations.
}R1 vs R0 surgery.36 years. In particular, two patients died from causes dir-
ectly related to the tumor treatment, and these data
deserve careful consideration if we assume that even
observation alone proved to be an effective option in
high-risk patients [10,11].
Conclusions
R0 surgery aided by IFS can decrease CR rate in patients
with AF. For patients with tumors confined to the limbs,
a particularly strict follow-up or non-surgical treatment
could be appropriate because of the high risk of recur-
rence after R0 surgery in this subgroup. In selected
cases, watchful waiting with close clinical follow-up
could represent a viable strategy for limb tumors smaller
than 5 cm [10,11]. Indeed, as the peculiar epidemiology
of this tumor is unlikely to empower generous trial
design, systematic risk weighting of individual compo-
nents is, therefore, the most reasonable way to stratify
patients and define a rationale for approaches other than
surgery or in combination with it.
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